<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33754495</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1755-5949</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>7</Issue><PubDate><Year>2021</Year><Month>Jul</Month></PubDate></JournalIssue><Title>CNS neuroscience &amp; therapeutics</Title><ISOAbbreviation>CNS Neurosci Ther</ISOAbbreviation></Journal><ArticleTitle>A bioisostere of Dimebon/Latrepirdine delays the onset and slows the progression of pathology in FUS transgenic mice.</ArticleTitle><Pagination><StartPage>765</StartPage><EndPage>775</EndPage><MedlinePgn>765-775</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/cns.13637</ELocationID><Abstract><AbstractText Label="AIMS">To assess effects of DF402, a bioisostere of Dimebon/Latrepirdine, on the disease progression in the transgenic model of amyotrophic lateral sclerosis (ALS) caused by expression of pathogenic truncated form of human FUS protein.</AbstractText><AbstractText Label="METHODS">Mice received DF402 from the age of 42&#xa0;days and the onset of clinical signs, the disease duration and animal lifespan were monitored for experimental and control animals, and multiple parameters of their gait were assessed throughout the pre-symptomatic stage using CatWalk system followed by a bioinformatic analysis. RNA-seq was used to compare the spinal cord transcriptomes of wild-type, untreated, and DF402-treated FUS transgenic mice.</AbstractText><AbstractText Label="RESULTS">DF402 delays the onset and slows the progression of pathology. We developed a CatWalk analysis protocol that allows detection of gait changes in FUS transgenic mice and the effect of DF402 on their gait already at early pre-symptomatic stage. At this stage, a limited number of genes significantly change expression in transgenic mice and for 60% of these genes, DF402 treatment causes the reversion of the expression pattern.</AbstractText><AbstractText Label="CONCLUSION">DF402 slows down the disease progression in the mouse model of ALS, which is consistent with previously reported neuroprotective properties of Dimebon and its other bioisosteres. These results suggest that these structures can be considered as lead compounds for further optimization to obtain novel medicines that might be used as components of complex ALS therapy.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors. CNS Neuroscience &amp; Therapeutics published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chaprov</LastName><ForeName>Kirill</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Physiologically Active Compounds, Russian Academy of Science, Chernogolovka, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rezvykh</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Moscow Institute of Physics and Technology, Dolgoprudny, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Funikov</LastName><ForeName>Sergei</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ivanova</LastName><ForeName>Tamara A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Institute of Physiologically Active Compounds, Russian Academy of Science, Chernogolovka, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lysikova</LastName><ForeName>Ekaterina A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Institute of Physiologically Active Compounds, Russian Academy of Science, Chernogolovka, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deykin</LastName><ForeName>Alexei V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Genome Editing for Veterinary and Biomedicine, Belgorod State National Research University, Belgorod region, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kukharsky</LastName><ForeName>Michail S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Institute of Physiologically Active Compounds, Russian Academy of Science, Chernogolovka, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pirogov Russian National Research Medical University, Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Biosciences, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu Aksinenko</LastName><ForeName>Alexey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Physiologically Active Compounds, Russian Academy of Science, Chernogolovka, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bachurin</LastName><ForeName>Sergey O</ForeName><Initials>SO</Initials><AffiliationInfo><Affiliation>Institute of Physiologically Active Compounds, Russian Academy of Science, Chernogolovka, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ninkina</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-8570-5648</Identifier><AffiliationInfo><Affiliation>Institute of Physiologically Active Compounds, Russian Academy of Science, Chernogolovka, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Biosciences, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buchman</LastName><ForeName>Vladimir L</ForeName><Initials>VL</Initials><Identifier Source="ORCID">0000-0002-7631-8352</Identifier><AffiliationInfo><Affiliation>Institute of Physiologically Active Compounds, Russian Academy of Science, Chernogolovka, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Biosciences, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>075-15-2019-1661</GrantID><Agency>Ministry of Science and Higher Education of the Russian Federation</Agency><Country/></Grant><Grant><GrantID>&#x41c;&#x41a;-3316.2019.4</GrantID><Agency>Russian President Foundation</Agency><Country/></Grant><Grant><GrantID>20-34-90028</GrantID><Agency>Russian Foundation for Basic Research</Agency><Country/></Grant><Grant><GrantID>0090-2019-0005</GrantID><Agency>State Assignment of IPAC RAS</Agency><Country/></Grant><Grant><GrantID>Buchman/Apr13/6096</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>CNS Neurosci Ther</MedlineTA><NlmUniqueID>101473265</NlmUniqueID><ISSNLinking>1755-5930</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000599550">FUS protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical><Chemical><RegistryNumber>OD9237K1Z6</RegistryNumber><NameOfSubstance UI="C010119">latrepirdine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005684" MajorTopicYN="N">Gait</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS mouse model</Keyword><Keyword MajorTopicYN="N">FUS</Keyword><Keyword MajorTopicYN="N">TLS</Keyword><Keyword MajorTopicYN="N">drug effects</Keyword><Keyword MajorTopicYN="N">gamma-carbolines</Keyword><Keyword MajorTopicYN="N">motor neuron disease</Keyword></KeywordList><CoiStatement>The authors have declared no competing interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>23</Day><Hour>7</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33754495</ArticleId><ArticleId IdType="pmc">PMC8193697</ArticleId><ArticleId IdType="doi">10.1111/cns.13637</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dash RP, Babu RJ, Srinivas NR. Two decades&#x2010;long journey from riluzole to edaravone: revisiting the clinical pharmacokinetics of the only two amyotrophic lateral sclerosis therapeutics. Clin Pharmacokinet. 2018;57(11):1385&#x2010;1398.</Citation><ArticleIdList><ArticleId IdType="pubmed">29682695</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal MK. Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med Res Rev. 2019;39(2):733&#x2010;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Wobst HJ, Mack KL, Brown DG, Brandon NJ, Shorter J. The clinical trial landscape in amyotrophic lateral sclerosis&#x2010;past, present, and future. Med Res Rev. 2020;40(4):1352&#x2010;1384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7417284</ArticleId><ArticleId IdType="pubmed">32043626</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukharsky MS, Skvortsova VI, Bachurin SO, Buchman VL. In a search for efficient treatment for amyotrophic lateral sclerosis: old drugs for new approaches. Med Res Rev. 2020. [Epub ahead of print]. 10.1002/med.21725</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21725</ArticleId><ArticleId IdType="pubmed">32815157</ArticleId></ArticleIdList></Reference><Reference><Citation>Pieper AA, Xie S, Capota E, et al. Discovery of a proneurogenic, neuroprotective chemical. Cell. 2010;142(1):39&#x2010;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2930815</ArticleId><ArticleId IdType="pubmed">20603013</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jesus&#x2010;Cortes H, Xu P, Drawbridge J, et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson disease. Proc Natl Acad Sci U S A. 2012;109(42):17010&#x2010;17015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3479520</ArticleId><ArticleId IdType="pubmed">23027934</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesla R, Wolf HP, Xu P, et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2012;109(42):17016&#x2010;17021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3479516</ArticleId><ArticleId IdType="pubmed">23027932</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez SE, Nadeem M, Sadleir KR, et al. Dimebon alters hippocampal amyloid pathology in 3xTg&#x2010;AD mice. Int J Physiol Pathophysiol Pharmacol. 2012;4(3):115&#x2010;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3466490</ArticleId><ArticleId IdType="pubmed">23071869</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters OM, Connor&#x2010;Robson N, Sokolov VB, et al. Chronic administration of dimebon ameliorates pathology in TauP301S transgenic mice. J Alzheimers Dis. 2013;33(4):1041&#x2010;1049.</Citation><ArticleIdList><ArticleId IdType="pubmed">23099813</ArticleId></ArticleIdList></Reference><Reference><Citation>Steele JW, Lachenmayer ML, Ju S, et al. Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model. Mol Psychiatry. 2013;18(8):889&#x2010;897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3625697</ArticleId><ArticleId IdType="pubmed">22850627</ArticleId></ArticleIdList></Reference><Reference><Citation>Bharadwaj PR, Bates KA, Porter T, et al. Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases. Transl Psychiatry. 2013;3:e332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4030329</ArticleId><ArticleId IdType="pubmed">24301650</ArticleId></ArticleIdList></Reference><Reference><Citation>Strekalova T, Bahzenova N, Trofimov A, et al. Pro&#x2010;neurogenic, memory&#x2010;enhancing and anti&#x2010;stress effects of DF302, a novel fluorine gamma&#x2010;carboline derivative with multi&#x2010;target mechanism of action. Mol Neurobiol. 2018;55(1):335&#x2010;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">28856531</ArticleId></ArticleIdList></Reference><Reference><Citation>Skvortsova VI, Bachurin SO, Ustyugov AA, et al. Gamma&#x2010;carbolines derivatives as promising agents for the development of pathogenic therapy for proteinopathy. Acta Naturae. 2018;10(4):59&#x2010;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6351039</ArticleId><ArticleId IdType="pubmed">30713762</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachurin SO, Gavrilova SI, Samsonova A, Barreto GE, Aliev G. Mild cognitive impairment due to Alzheimer disease: contemporary approaches to diagnostics and pharmacological intervention. Pharmacol Res. 2018;129:216&#x2010;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">29170097</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Li Q, Bezprozvanny I. Evaluation of dimebon in cellular model of Huntington's disease. Mol Neurodegener. 2008;3:15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577671</ArticleId><ArticleId IdType="pubmed">18939977</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Hedskog L, Petersen CA, Winblad B, Ankarcrona M. Dimebon (latrepirdine) enhances mitochondrial function and protects neuronal cells from death. J Alzheimers Dis. 2010;21(2):389&#x2010;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">20555134</ArticleId></ArticleIdList></Reference><Reference><Citation>Malatynska E, Steinbusch HW, Redkozubova O, et al. Anhedonic&#x2010;like traits and lack of affective deficits in 18&#x2010;month&#x2010;old C57BL/6 mice: implications for modeling elderly depression. Exp Gerontol. 2012;47(8):552&#x2010;564.</Citation><ArticleIdList><ArticleId IdType="pubmed">22583982</ArticleId></ArticleIdList></Reference><Reference><Citation>Vignisse J, Steinbusch HW, Bolkunov A, et al. Dimebon enhances hippocampus&#x2010;dependent learning in both appetitive and inhibitory memory tasks in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(2):510&#x2010;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">21163318</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckert SH, Eckmann J, Renner K, Eckert GP, Leuner K, Muller WE. Dimebon ameliorates amyloid&#x2010;beta induced impairments of mitochondrial form and function. J Alzheimers Dis. 2012;31(1):21&#x2010;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">22475801</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisova P, Alvarez SP, Kilbride SM, et al. Latrepirdine is a potent activator of AMP&#x2010;activated protein kinase and reduces neuronal excitability. Transl Psychiatry. 2013;3:e317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3818013</ArticleId><ArticleId IdType="pubmed">24150226</ArticleId></ArticleIdList></Reference><Reference><Citation>Steele JW, Gandy S. Latrepirdine (Dimebon(R)), a potential Alzheimer therapeutic, regulates autophagy and neuropathology in an Alzheimer mouse model. Autophagy. 2013;9(4):617&#x2010;618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3627679</ArticleId><ArticleId IdType="pubmed">23380933</ArticleId></ArticleIdList></Reference><Reference><Citation>Steele JW, Ju S, Lachenmayer ML, et al. Latrepirdine stimulates autophagy and reduces accumulation of alpha&#x2010;synuclein in cells and in mouse brain. Mol Psychiatry. 2013;18(8):882&#x2010;888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3523214</ArticleId><ArticleId IdType="pubmed">22869031</ArticleId></ArticleIdList></Reference><Reference><Citation>Egea J, Romero A, Parada E, Leon R, Dal&#x2010;Cim T, Lopez MG. Neuroprotective effect of dimebon against ischemic neuronal damage. Neuroscience. 2014;267:11&#x2010;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">24607349</ArticleId></ArticleIdList></Reference><Reference><Citation>Shevtsova EF, Vinogradova DV, Kireeva EG, Reddy VP, Aliev G, Bachurin SO. Dimebon attenuates the Abeta&#x2010;induced mitochondrial permeabilization. Curr Alzheimer Res. 2014;11(5):422&#x2010;429.</Citation><ArticleIdList><ArticleId IdType="pubmed">24801220</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang CC, Kuo JR, Wang SJ. Dimebon, an antihistamine drug, inhibits glutamate release in rat cerebrocortical nerve terminals. Eur J Pharmacol. 2014;734:67&#x2010;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">24726847</ArticleId></ArticleIdList></Reference><Reference><Citation>Ustyugov A, Shevtsova E, Bachurin S. Novel sites of neuroprotective action of Dimebon (Latrepirdine). Mol Neurobiol. 2015;52(2):970&#x2010;978.</Citation><ArticleIdList><ArticleId IdType="pubmed">26123670</ArticleId></ArticleIdList></Reference><Reference><Citation>Porter T, Bharadwaj P, Groth D, et al. The effects of latrepirdine on amyloid&#x2010;beta aggregation and toxicity. J Alzheimers Dis. 2015;50(3):895&#x2010;905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4927897</ArticleId><ArticleId IdType="pubmed">26836170</ArticleId></ArticleIdList></Reference><Reference><Citation>Coughlan KS, Mitchem MR, Hogg MC, Prehn JH. "Preconditioning" with latrepirdine, an adenosine 5'&#x2010;monophosphate&#x2010;activated protein kinase activator, delays amyotrophic lateral sclerosis progression in SOD1(G93A) mice. Neurobiol Aging. 2015;36(2):1140&#x2010;1150.</Citation><ArticleIdList><ArticleId IdType="pubmed">25443289</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita M, Nonaka T, Arai T, et al. Methylene blue and dimebon inhibit aggregation of TDP&#x2010;43 in cellular models. FEBS Lett. 2009;583(14):2419&#x2010;2424.</Citation><ArticleIdList><ArticleId IdType="pubmed">19560462</ArticleId></ArticleIdList></Reference><Reference><Citation>Khritankova IV, Kukharskiy MS, Lytkina OA, Bachurin SO, Shorning BY. Dimebon activates autophagosome components in human neuroblastoma SH&#x2010;SY5Y cells. Dokl Biochem Biophys. 2012;446:251&#x2010;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">23132721</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachurin SO, Shelkovnikova TA, Ustyugov AA, et al. Dimebon slows progression of proteinopathy in gamma&#x2010;synuclein transgenic mice. Neurotox Res. 2012;22(1):33&#x2010;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3351599</ArticleId><ArticleId IdType="pubmed">22179976</ArticleId></ArticleIdList></Reference><Reference><Citation>Bronovitsky EV, Deikin AV, Ermolkevich TG, et al. Gamma&#x2010;carboline inhibits neurodegenerative processes in a transgenic model of amyotrophic lateral sclerosis. Dokl Biochem Biophys. 2015;462:189&#x2010;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">26163217</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelkovnikova TA, Peters OM, Deykin AV, et al. Fused in Sarcoma (FUS) Protein Lacking Nuclear Localization Signal (NLS) and major RNA binding motifs triggers proteinopathy and severe motor phenotype in transgenic mice. J Biol Chem. 2013;288(35):25266&#x2010;25274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3757190</ArticleId><ArticleId IdType="pubmed">23867462</ArticleId></ArticleIdList></Reference><Reference><Citation>Lysikova EA, Funikov S, Rezvykh AP, et al. Low level of expression of C&#x2010;terminally truncated human FUS causes extensive changes in the spinal cord transcriptome of asymptomatic transgenic mice. Neurochem Res. 2020;45(5):1168&#x2010;1179.</Citation><ArticleIdList><ArticleId IdType="pubmed">32157564</ArticleId></ArticleIdList></Reference><Reference><Citation>Lysikova EA, Kukharsky MS, Chaprov KD, et al. Behavioural impairments in mice of a novel FUS transgenic line recapitulate features of frontotemporal lobar degeneration. Genes Brain Behav. 2019;18(8):e12607.</Citation><ArticleIdList><ArticleId IdType="pubmed">31437340</ArticleId></ArticleIdList></Reference><Reference><Citation>Percie du Sert N, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. J Cereb Blood Flow Metab. 2020;40(9):1769&#x2010;1777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7430098</ArticleId><ArticleId IdType="pubmed">32663096</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachurin SO, Ustyugov AA, Ninkina NN, et al. Russian Patent 2 490 268 C2; 2011.</Citation></Reference><Reference><Citation>Peters OM, Shelkovnikova T, Tarasova T, et al. Chronic administration of Dimebon does not ameliorate amyloid&#x2010;beta pathology in 5xFAD transgenic mice. J Alzheimers Dis. 2013;36(3):589&#x2010;596.</Citation><ArticleIdList><ArticleId IdType="pubmed">23645096</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamers FP, Lankhorst AJ, van Laar TJ, Veldhuis WB, Gispen WH. Automated quantitative gait analysis during overground locomotion in the rat: its application to spinal cord contusion and transection injuries. J Neurotrauma. 2001;18(2):187&#x2010;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">11229711</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamers FP, Koopmans GC, Joosten EA. CatWalk&#x2010;assisted gait analysis in the assessment of spinal cord injury. J Neurotrauma. 2006;23(3&#x2013;4):537&#x2010;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">16629635</ArticleId></ArticleIdList></Reference><Reference><Citation>Batka RJ, Brown TJ, McMillan KP, Meadows RM, Jones KJ, Haulcomb MM. The need for speed in rodent locomotion analyses. Anat Rec. 2014;297(10):1839&#x2010;1864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4758221</ArticleId><ArticleId IdType="pubmed">24890845</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchman VL, Hunter HJ, Pinon LG, et al. Persyn, a member of the synuclein family, has a distinct pattern of expression in the developing nervous system. J Neurosci. 1998;18(22):9335&#x2010;9341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792889</ArticleId><ArticleId IdType="pubmed">9801372</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Brien RG, Kaiser MK. MANOVA method for analyzing repeated measures designs: an extensive primer. Psychol Bull. 1985;97(2):316&#x2010;333.</Citation><ArticleIdList><ArticleId IdType="pubmed">3983301</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J. Geometric structure of high&#x2010;dimensional data and dimensionality reduction. Beijing, China: Higher Education Press; Heidelberg; New York: Springer; 2012.</Citation></Reference><Reference><Citation>Krasnov GS, Dmitriev AA, Kudryavtseva AV, et al. PPLine: an automated pipeline for SNP, SAP, and splice variant detection in the context of proteogenomics. J Proteome Res. 2015;14(9):3729&#x2010;3737.</Citation><ArticleIdList><ArticleId IdType="pubmed">26147802</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139&#x2010;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284&#x2010;287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA&#x2010;sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Funikov SY, Rezvykh AP, Mazin PV, et al. FUS(1&#x2013;359) transgenic mice as a model of ALS: pathophysiological and molecular aspects of the proteinopathy. Neurogenetics. 2018;19(3):189&#x2010;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">29982879</ArticleId></ArticleIdList></Reference><Reference><Citation>Millership S, Ninkina N, Guschina IA, et al. Increased lipolysis and altered lipid homeostasis protect gamma&#x2010;synuclein&#x2010;null mutant mice from diet&#x2010;induced obesity. Proc Natl Acad Sci U S A. 2012;109(51):20943&#x2010;20948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3529034</ArticleId><ArticleId IdType="pubmed">23213245</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu IM, Morimoto ET, Goodarzi H, et al. A neurodegeneration&#x2010;specific gene&#x2010;expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep. 2013;4(2):385&#x2010;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4272581</ArticleId><ArticleId IdType="pubmed">23850290</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay U, Cotney J, Nagy M, et al. RNA&#x2010;Seq profiling of spinal cord motor neurons from a presymptomatic SOD1 ALS mouse. PLoS One. 2013;8(1):e53575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3536741</ArticleId><ArticleId IdType="pubmed">23301088</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimprich A, Ostereicher MA, Becker L, et al. Analysis of locomotor behavior in the German Mouse Clinic. J Neurosci Methods. 2018;300:77&#x2010;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">28483715</ArticleId></ArticleIdList></Reference><Reference><Citation>Timotius IK, Moceri S, Plank AC, et al. Silhouette&#x2010;length&#x2010;scaled gait parameters for motor functional analysis in mice and rats. eNeuro. 2019;6(6):ENEURO.0100&#x2010;19.2019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6825954</ArticleId><ArticleId IdType="pubmed">31604813</ArticleId></ArticleIdList></Reference><Reference><Citation>Timotius IK, Canneva F, Minakaki G, et al. Systematic data analysis and data mining in CatWalk gait analysis by heat mapping exemplified in rodent models for neurodegenerative diseases. J Neurosci Methods. 2019;326:108367.</Citation><ArticleIdList><ArticleId IdType="pubmed">31351096</ArticleId></ArticleIdList></Reference><Reference><Citation>Minakaki G, Canneva F, Chevessier F, et al. Treadmill exercise intervention improves gait and postural control in alpha&#x2010;synuclein mouse models without inducing cerebral autophagy. Behav Brain Res. 2019;363:199&#x2010;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">30599154</ArticleId></ArticleIdList></Reference><Reference><Citation>Koivisto H, Ytebrouck E, Carmans S, et al. Progressive age&#x2010;dependent motor impairment in human tau P301S overexpressing mice. Behav Brain Res. 2019;376:112158.</Citation><ArticleIdList><ArticleId IdType="pubmed">31442549</ArticleId></ArticleIdList></Reference><Reference><Citation>Watkins J, Ghosh A, Keerie AFA, Alix JJP, Mead RJ, Sreedharan J. Female sex mitigates motor and behavioural phenotypes in TDP&#x2010;43(Q331K) knock&#x2010;in mice. Sci Rep. 2020;10(1):19220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7645778</ArticleId><ArticleId IdType="pubmed">33154447</ArticleId></ArticleIdList></Reference><Reference><Citation>Munter J, Babaevskaya D, Wolters EC, et al. Molecular and behavioural abnormalities in the FUS&#x2010;tg mice mimic frontotemporal lobar degeneration: Effects of old and new anti&#x2010;inflammatory therapies. J Cell Mol Med. 2020;24(17):10251&#x2010;10257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7520339</ArticleId><ArticleId IdType="pubmed">32667139</ArticleId></ArticleIdList></Reference><Reference><Citation>de Munter J, Shafarevich I, Liundup A, et al. Neuro&#x2010;cells therapy improves motor outcomes and suppresses inflammation during experimental syndrome of amyotrophic lateral sclerosis in mice. CNS Neurosci Ther. 2020;26(5):504&#x2010;517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7163689</ArticleId><ArticleId IdType="pubmed">31867846</ArticleId></ArticleIdList></Reference><Reference><Citation>Sambon M, Gorlova A, Demelenne A, et al. Dibenzoylthiamine has powerful antioxidant and anti&#x2010;inflammatory properties in cultured cells and in mouse models of stress and neurodegeneration. Biomedicines. 2020;8(9):361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7555733</ArticleId><ArticleId IdType="pubmed">32962139</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogg MC, Halang L, Woods I, Coughlan KS, Prehn JHM. Riluzole does not improve lifespan or motor function in three ALS mouse models. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(5&#x2010;6):438&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">29221425</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerga A, Hallier M, Delva L, et al. Identification of an RNA binding specificity for the potential splicing factor TLS. J Biol Chem. 2001;276(9):6807&#x2010;6816.</Citation><ArticleIdList><ArticleId IdType="pubmed">11098054</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentmann E, Neumann M, Tahirovic S, Rodde R, Dormann D, Haass C. Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA&#x2010;binding protein of 43 kDa (TDP&#x2010;43). J Biol Chem. 2012;287(27):23079&#x2010;23094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3391091</ArticleId><ArticleId IdType="pubmed">22563080</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelkovnikova TA, Robinson HK, Connor&#x2010;Robson N, Buchman VL. Recruitment into stress granules prevents irreversible aggregation of FUS protein mislocalized to the cytoplasm. Cell Cycle. 2013;12(19):3194&#x2010;3202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3865015</ArticleId><ArticleId IdType="pubmed">24013423</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Niu C, Ren J, et al. The RRM domain of human fused in sarcoma protein reveals a non&#x2010;canonical nucleic acid binding site. Biochim Biophys Acta. 2013;1832(2):375&#x2010;385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3534766</ArticleId><ArticleId IdType="pubmed">23200923</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>